Here, we show that dasatinib, a small tyrosine kinase inhibitor with intermediate selectivity (Karaman et al., 2008; Shah et al., 2004), restricts MMP13 upregulation and metastatic dissemination of breast cancer cells once the NRG–HER signaling axis is activated. The gene discussed is MMP13; the disease is breast cancer.